Niuliva (Human Hepatitis B Immunoglobulin)

The product contains high‑titer anti‑HBs antibodies that bind directly to hepatitis B virus particles. This neutralizes the virus, prevents it from entering liver cells, and promotes clearance through immune complex formation, offering immediate protection while the patient’s own immune system responds.

The dose of Niuliva is determined by the prescribing clinician based on the patient’s weight, indication, and clinical situation. Healthcare professionals calculate the appropriate volume and infusion rate according to established guidelines and the product’s prescribing information.

Safety data for Niuliva in pregnancy and lactation are limited. The product should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician after careful assessment.

To order Niuliva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling), and necessary import documentation.

Niuliva provides immediate passive immunity through antibodies, whereas hepatitis B vaccines stimulate active immunity over weeks. In situations requiring rapid protection—such as after accidental exposure or in newborns of infected mothers—Niuliva offers a faster protective effect, often used in conjunction with vaccination for long‑term immunity.

Niuliva must be stored at 2‑8 °C in a refrigerator, protected from light. It should not be frozen or shaken. Prior to administration, allow the product to reach room temperature if required, and inspect for any particulate matter or discoloration.

Niuliva is given by intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate is controlled to minimize adverse reactions, and patients are monitored for vital signs and signs of hypersensitivity throughout the administration.

The most serious risks include severe allergic reactions such as anaphylaxis, serum sickness, acute renal dysfunction, and thromboembolic events. Prompt recognition and management of these reactions are essential, and patients should be observed closely during and after infusion.

Niuliva should not be administered to individuals with a known severe IgA deficiency who have experienced prior reactions to immunoglobulin products, or to patients with a documented hypersensitivity to any component of the formulation. Contraindications are determined by the prescribing clinician.